Caitong International Asset Management Co. Ltd Has $32,000 Holdings in Revvity Inc. $RVTY

Caitong International Asset Management Co. Ltd cut its position in Revvity Inc. (NYSE:RVTY) by 53.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 326 shares of the company’s stock after selling 368 shares during the quarter. Caitong International Asset Management Co. Ltd’s holdings in Revvity were worth $32,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of the stock. Ethic Inc. boosted its holdings in Revvity by 7.7% in the 2nd quarter. Ethic Inc. now owns 14,419 shares of the company’s stock valued at $1,410,000 after purchasing an additional 1,028 shares during the period. Otter Creek Advisors LLC lifted its holdings in shares of Revvity by 74.2% during the 2nd quarter. Otter Creek Advisors LLC now owns 39,963 shares of the company’s stock worth $3,865,000 after acquiring an additional 17,023 shares during the period. Generali Asset Management SPA SGR bought a new position in shares of Revvity during the 2nd quarter worth about $1,179,000. Sequoia Financial Advisors LLC lifted its holdings in shares of Revvity by 10.2% during the 2nd quarter. Sequoia Financial Advisors LLC now owns 30,778 shares of the company’s stock worth $2,977,000 after acquiring an additional 2,857 shares during the period. Finally, Vanguard Personalized Indexing Management LLC lifted its holdings in shares of Revvity by 4.3% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 16,410 shares of the company’s stock worth $1,587,000 after acquiring an additional 675 shares during the period. 86.65% of the stock is owned by institutional investors.

Revvity Trading Up 1.4%

Shares of NYSE RVTY opened at $98.91 on Monday. Revvity Inc. has a 1-year low of $81.36 and a 1-year high of $129.50. The company has a market cap of $11.48 billion, a PE ratio of 41.91, a P/E/G ratio of 3.30 and a beta of 0.98. The company has a current ratio of 3.33, a quick ratio of 2.75 and a debt-to-equity ratio of 0.43. The company has a 50-day moving average of $89.38 and a two-hundred day moving average of $92.37.

Revvity (NYSE:RVTY) last announced its earnings results on Monday, July 28th. The company reported $1.18 earnings per share for the quarter, topping analysts’ consensus estimates of $1.14 by $0.04. Revvity had a net margin of 10.19% and a return on equity of 7.66%. The company had revenue of $720.28 million during the quarter, compared to the consensus estimate of $711.26 million. During the same period in the previous year, the firm posted $1.22 earnings per share. The company’s revenue was up 4.1% on a year-over-year basis. As a group, equities analysts expect that Revvity Inc. will post 4.94 earnings per share for the current fiscal year.

Revvity Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, February 6th. Stockholders of record on Friday, January 16th will be given a dividend of $0.07 per share. The ex-dividend date is Friday, January 16th. This represents a $0.28 annualized dividend and a dividend yield of 0.3%. Revvity’s payout ratio is currently 11.86%.

Wall Street Analyst Weigh In

A number of research firms have recently commented on RVTY. Evercore ISI reduced their price objective on shares of Revvity from $108.00 to $106.00 and set an “outperform” rating for the company in a report on Tuesday, October 7th. Wall Street Zen cut shares of Revvity from a “buy” rating to a “hold” rating in a research report on Sunday, August 3rd. Weiss Ratings reiterated a “sell (d+)” rating on shares of Revvity in a research report on Saturday. Bank of America dropped their target price on shares of Revvity from $110.00 to $99.00 and set a “buy” rating for the company in a research report on Monday, September 22nd. Finally, Barclays dropped their target price on shares of Revvity from $110.00 to $100.00 and set an “overweight” rating for the company in a research report on Thursday, October 2nd. Nine analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $116.38.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.